1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)" is currently closed and not accepting applications.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) is sponsored by National Institutes of Health (NIH). This SBIR program seeks to apply artificial intelligence (AI) and machine learning (ML) technologies to accelerate drug discovery for substance use disorders (SUDs).
It supports identifying novel targets, designing new molecules, conducting virtual preclinical studies, and analyzing preclinical and clinical data.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-DA-25-054 Funding Opportunity Title:Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Expected Number of Awards: Assistance Listings:93.
279 -- Drug Abuse and Addiction Research Programs Cost Sharing or Matching Requirement:No Last Updated Date:Jan 29, 2024 Original Closing Date for Applications:Jul 25, 2024 Current Closing Date for Applications:Jul 25, 2024 Archive Date:Aug 30, 2024 Estimated Total Program Funding: Eligible Applicants:Small businesses Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
## Additional Information Agency Name:National Institutes of Health Description:The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions Link to Additional Information:https://grants.
nih. gov/grants/guide/rfa-files/RFA-DA-25-054. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: See Section VII.
Agency Contacts within the full opportunity announcement for all other inquires. #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below.
This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: Small businesses, with a focus on those utilizing AI/ML for drug discovery, particularly for substance use disorders. Confirm the full requirements in the official notice before applying.
The published deadline was July 25, 2024, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article